Skip to Content

Join the 'Leishmaniasis' group to help and get support from people like you.

Leishmaniasis News

Related terms: Cutaneous Leishmaniasis

Impavido Approved to Treat Tropical Parasitic Disease

Posted 28 Apr 2014 by Drugs.com

THURSDAY, March 20, 2014 – Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies. Most Americans who contract the disease do so traveling overseas, the agency said in a news release. The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women. Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, abdominal pain, itching, fatigue and elevated liver enzymes, the FDA said. The drug is produced by Paladin Therapeutics, based in Montreal. More information The U.S. Centers for Disease Control and Prevention has more about ... Read more

Related support groups: Leishmaniasis, Miltefosine

FDA Approves Impavido to Treat Tropical Disease Leishmaniasis

Posted 20 Mar 2014 by Drugs.com

March 19, 2014 – The U.S. Food and Drug Administration today approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and subtropics. Most U.S. patients acquire leishmaniasis overseas. Impavido is an oral medicine approved to treat the three main types of leishmaniasis: visceral leishmaniasis (affects internal organs), cutaneous leishmaniasis (affects the skin) and mucosal leishmaniasis (affects the nose and throat). It is intended for patients 12 years of age and older. Impavido is the first FDA-approved drug to treat cutaneous or mucosal leishmaniasis. “Today’s approval demonstrates the FDA’s commitment to making available therapeutic options to treat tropical diseases,” said Edward ... Read more

Related support groups: Leishmaniasis

Heat Therapy Helps Treat U.S. Soldiers' Infections

Posted 11 Mar 2010 by Drugs.com

THURSDAY, March 11 – Heat therapy is effective for treating lesions caused by a parasitic skin infection that afflicts U.S. soldiers in Iraq and Afghanistan, a new study shows. Since U.S. operations began in those countries, more than 1,300 American military and civilian personnel have developed Leishmania major skin lesions, according to information in a news release about the study. Naomi Aronson and her colleagues at the Uniformed Services University of the Health Sciences and Walter Reed Army Medical Center looked at 56 military personal with these skin lesions and found that a single session with a ThermoMed device appeared to be as effective as the current standard therapy involving a 10-day intravenous course of sodium stibogluconate (Pentostam). Both treatments showed comparable rates of healing. The number and severity of side effects was greater with sodium stibogluconate ... Read more

Related support groups: Leishmaniasis

Ask a Question

Further Information

Related Condition Support Groups

Infections

Related Drug Support Groups

allopurinol, amphotericin b, Nebupent, AmBisome, amphotericin b lipid complex, amphotericin b liposomal, Abelcet, Pentam, Fungizone, view more... pentamidine, miltefosine, Pentacarinat, Impavido, Pentam 300, Amphotec, Amphocin, amphotericin b cholesteryl sulfate